Cardiovascular Function and Exercise Capacity in Childhood Cancer Survivors

Childhood cancer survivors (CCS) might be at high risk of additional chronic diseases due to cardiotoxic side effects. The aim of this study was to analyze long-term side effects of cancer therapy on vascular structure/function, cardiac biomarkers and on physical activity. In total, 68 asymptomatic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-01, Vol.11 (3), p.628
Main Authors: Reiner, Barbara, Schmid, Irene, Schulz, Thorsten, Müller, Jan, Hager, Alfred, Hock, Julia, Ewert, Peter, Wolf, Cordula, Oberhoffer-Fritz, Renate, Weil, Jochen
Format: Article
Language:English
Subjects:
Age
Asymptomatic
Atherosclerosis
Biomarkers
Blood pressure
Cancer therapies
Cardiology
Cardiotoxicity
Childhood
Cholesterol
Clinical medicine
Exercise
High density lipoprotein
Laboratories
Metabolism
Mortality
Patients
Pediatrics
Peptides
Physical fitness
Radiation
Regression analysis
Risk factors
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Childhood cancer survivors (CCS) might be at high risk of additional chronic diseases due to cardiotoxic side effects. The aim of this study was to analyze long-term side effects of cancer therapy on vascular structure/function, cardiac biomarkers and on physical activity. In total, 68 asymptomatic patients aged 16-30 years with childhood cancer (diagnosed 10.6 ± 3.9 years ago) were examined from 2015-2020. (Central) blood pressure and pulse wave velocity were registered via the oscillometric method, while carotid intima-media thickness (cIMT) was measured non-invasively by ultrasound. cIMT values of patients were compared to healthy controls ( = 68; aged 22.3 ± 3.5 years). Patients' exercise capacity was recorded. The plasma N-terminal pro-brain natriuretic protein (NTproBNP) and troponin levels were measured as cardiac biomarkers. CCS were categorized in groups with low, moderate and high anthracyclines. No differences were found in cIMT between patients and controls as well as between patients with various anthracycline dosage. Patients with high dose anthracyclines showed a significant lower performance versus patients with moderate dose anthracyclines (84.4% of predicted VO peak; = 0.017). A total of 11.6% of CCS had abnormal NTproBNP values which correlated with received anthracycline dosage ( = 0.024; r = 0.343). NTproBNP levels and exercise capacity might be early markers for cardiovascular dysfunction in CCS and should be included in a follow-up protocol, while cIMT and troponin seem not to be adequate parameters.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11030628